Great Point Partners Acquires Germany's Lyocontract GmbH Drug CDMO

26 Sep, 2024

Great Point Partners Acquires Germany's Lyocontract GmbH Drug CDMO

Great Point Partners (GPP), an investment firm based in Greenwich, Conn., has announced the acquisition of Lyocontract GmbH, a prominent contract development and manufacturing organization (CDMO) located in Ilsenburg, Germany. Founded in 2007, Lyocontract specializes in aseptic liquid filling, lyophilization, and packaging services, adhering to the European Union's Annex 1 standards. The company is recognized for its expertise in producing liquid and freeze-dried parenteral drugs for both clinical and commercial use.

This acquisition marks the first investment made by GPP's European team, which operates from their new London office. GPP aims to assist growing healthcare companies in expanding their global reach and entering the U.S. market. According to Noah Rhodes, Managing Director at GPP, Lyocontract is well-positioned to scale its operations and enhance its global capabilities amidst increasing demand for lyophilization services.

The investment emphasizes GPP's commitment to supporting exceptional management teams with a competitive edge in the industry. Dr. Tino Galgon, CEO of Lyocontract, expressed enthusiasm for the growth opportunities ahead, highlighting the invaluable support GPP will provide in enhancing contract manufacturing capabilities and distribution reach. Rantum Capital facilitated debt financing for this acquisition.